Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(3.19)
# 1,175
Out of 4,996 analysts
57
Total ratings
43.14%
Success rate
4.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTSR Metsera | Reiterates: Overweight | n/a | $52.25 | - | 2 | Sep 3, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Overweight | n/a | $10.80 | - | 1 | Aug 15, 2025 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $25.00 | +160.00% | 13 | Jun 23, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $11.12 | - | 7 | May 6, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $25.30 | - | 3 | Apr 23, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $1.99 | - | 1 | Mar 18, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $16.05 | - | 3 | Jan 21, 2025 | |
| ATYR aTyr Pharma | Initiates: Overweight | n/a | $0.84 | - | 1 | Jan 6, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Overweight | $10 | $4.70 | +112.77% | 1 | Dec 17, 2024 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Neutral | n/a | $424.23 | - | 4 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $61.99 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $47.74 | - | 5 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $26.38 | - | 2 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $35.50 | -32.39% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.50 | +17,936.07% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $1.50 | +833.33% | 1 | Mar 3, 2021 |
Metsera
Sep 3, 2025
Reiterates: Overweight
Price Target: n/a
Current: $52.25
Upside: -
Avalo Therapeutics
Aug 15, 2025
Initiates: Overweight
Price Target: n/a
Current: $10.80
Upside: -
Structure Therapeutics
Jun 23, 2025
Reiterates: Overweight
Price Target: $65
Current: $25.00
Upside: +160.00%
ORIC Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: n/a
Current: $11.12
Upside: -
Travere Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $25.30
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.99
Upside: -
Keros Therapeutics
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $16.05
Upside: -
aTyr Pharma
Jan 6, 2025
Initiates: Overweight
Price Target: n/a
Current: $0.84
Upside: -
TriSalus Life Sciences
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $4.70
Upside: +112.77%
Madrigal Pharmaceuticals
Nov 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $424.23
Upside: -
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $61.99
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $47.74
Upside: -
Feb 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $26.38
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $35.50
Upside: -32.39%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $2.50
Upside: +17,936.07%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $1.50
Upside: +833.33%